Objective: To investigate the effects of dietary factors on the pre-eclampsia-like mouse model development at multiple stages of gestation.

Methods: Pre-eclampsia-like model was established in C57 wild-type (WT) and apoE(-/-) pregnant mice at early, middle and late gestational stages by injecting nitric oxide synthase (NOS) inhibitor L-arginine methyl ester (L-NAME) subcutaneously. Control groups received normal saline (NS) simultaneously. Each group was subdivided into standard chow subgroup (SC, n = 6) and high-fat diet subgroup (HF, n = 6). Blood pressure, urinary protein and plasma lipid were measured and fetal outcomes compared. Data were analyzed statistically.

Results: In early and middle L-NAME subgroups, the plasma concentrations of cholesterol (TC), triglyceride (TG) and free fatty acid (FFA) all increased. And the early L-NAME subgroup in apoE(-/-) mice was the most remarkable (P < 0.05). In apoE(-/-) groups (both L-NAME and NS groups), the plasma concentrations of total TC and TG were higher than those of WT groups (P < 0.05). But there was no significant difference in FFA between them. The plasma lipid levels of apoE(-/-) HF + L-NAME group were the highest among all the groups (P < 0.05). Fetal and placental weights significantly decreased in early and middle L-NAME groups in both apoE(-/-) and WT mice (P < 0.05). But no significant difference was found between late L-NAME subgroup and NS groups (P > 0.05). Compared with WT groups, the weights were lower in apoE(-/-) mice. The fetal and placental weights in HF groups were lower than SC groups and the changes in early HF + L-NAME subgroup in apoE(-/-) mice were the most remarkable (P < 0.05). A lower live fetal rate and a higher absorbed fetal rate were found in early L-NAME groups than those of the NS groups (P < 0.05).

Conclusion: Pre-eclampsia occurring at an early stage is more likely to have abnormal plasma lipid levels and adverse feto-placental outcomes. High-fat dietary may aggravate the impact of L-NAME pre-eclampsia on pregnancy outcomes at an early gestational stage especially in ApoE(-/-) mice.

Download full-text PDF

Source

Publication Analysis

Top Keywords

apoe-/- mice
20
plasma lipid
16
early middle
12
groups
12
early l-name
12
l-name subgroup
12
l-name groups
12
groups 005
12
l-name
10
apoe-/-
8

Similar Publications

Prophylactic and therapeutic effects of EsV3 on atherosclerotic lesions in ApoE mice.

BMC Cardiovasc Disord

January 2025

Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Background: Atherosclerosis (AS) is a major contributor to vascular disorders and represents a significant risk to human health. Currently, first-line pharmacotherapies are associated with substantial side effects, and the development of atherosclerosis is closely linked to dietary factors. This study evaluated the effects of a dietary supplement, EsV3, on AS in apolipoprotein E (ApoE) model mice.

View Article and Find Full Text PDF

Translational validity of mouse models of Alzheimer's disease (AD) is variable. Because change in weight is a well-documented precursor of AD, we investigated whether diversity of human AD risk weight phenotypes was evident in a longitudinally characterized cohort of 1,196 female and male humanized APOE (hAPOE) mice, monitored up to 28 months of age which is equivalent to 81 human years. Autoregressive Hidden Markov Model (AHMM) incorporating age, sex, and APOE genotype was employed to identify emergent weight trajectories and phenotypes.

View Article and Find Full Text PDF

Zhilong Huoxue Tongyu capsule protects against atherosclerosis by suppressing EndMT via modulating Hippo/YAP signaling pathway.

J Tradit Complement Med

November 2024

National Traditional Chinese Medicine Clinical Research Base and Drug Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China.

Background And Aim: Zhilong Huoxue Tongyu Capsule (ZL capsule) has been demonstrated to be an effective and widely-used traditional Chinese medicine (TCM) formula for the treatment of various diseases, especially for atherosclerosis (AS) related cardiovascular and cerebrovascular diseases. Reversal of endothelial-mesenchymal transition (EndMT) plays a crucial role in the cure of AS. But the curative impact of ZL capsule on EndMT remains obscure during the development of AS.

View Article and Find Full Text PDF

Background: Astaxanthin (ASX), a fat-soluble carotenoid mainly sourced from Haematococcus pluvialis, shows promise for clinical applications in chronic inflammatory diseases. This study investigates whether ASX can mitigate atherosclerosis (AS) by modulating macrophage ferroptosis and provides astaxanthin-loaded polylactic acid-glycolic acid nanoparticles (ASX-PLGA NPs) as comparison.

Method: ApoE-/- mice were fed a high-fat diet with ASX or statin intervention.

View Article and Find Full Text PDF

Background: Millions worldwide are exposed to elevated levels of arsenic that significantly increase their risk of developing atherosclerosis, a pathology primarily driven by immune cells. While the impact of arsenic on immune cell populations in atherosclerotic plaques has been broadly characterized, cellular heterogeneity is a substantial barrier to in-depth examinations of the cellular dynamics for varying immune cell populations.

Objectives: This study aimed to conduct single-cell multi-omics profiling of atherosclerotic plaques in apolipoprotein E knockout () mice to elucidate transcriptomic and epigenetic changes in immune cells induced by arsenic exposure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!